Hemogenyx Pharma Plc (AIM:HEMO) Collaboration with major US biotechnology company


Collaboration to further develop humanized mice as a tool for drug development and testing


Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it has entered into a collaboration with major US biotechnology company in a deal worth up to approximately $250,000 for Hemogenyx.


The collaboration follows on from the announcement made by the Company on 26 February 2018, which confirmed the filing of a provisional patent application relating to the Company’s development of a new type of humanized mice with a chimeric mouse-human blood system. These new humanized mice can be used for disease modelling and drug development.


This application of Hemogenyx’s humanized mice as a tool for drug development and testing forms the basis of the Company’s collaboration with the US biotech company. The collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the company, and has the potential to generate further income as the collaboration develops.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented“We are pleased to collaborate with a major US biotechnology company, a leader in the field of blood cancer treatment. As we mentioned in our previous announcement, our new type of humanized mice let us extend our work into other disease models and specific drug development. The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate.”


About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioningthe CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantationthe HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.


Share Talk road map of news updates 


Newly floated biotech Hemogenyx (LSE:HEMO) linked up with Oxford University to transform treatment of blood cancers 

November 13, 2017

Hemogenyx Pharmaceuticals Plc (LON:HEMO) University of Oxford collaboration 

November 20, 2017

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential 

December 8, 2017

Hemogenyx Pharma Plc (AIM:HEMO) Lead candidate shown to be effective in treatment of Leukemia 

February 26, 2018

Hemogenyx Pharma Plc (AIM:HEMO) Video & Research Notes 

March 1, 2018



Full Research Note LINK HERE


Published on Feb 27, 2018


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned


Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.